Journal: Journal of Translational Medicine
Article Title: Ruxolitinib suppresses liver fibrosis progression and accelerates fibrosis reversal via selectively targeting Janus kinase 1/2
doi: 10.1186/s12967-022-03366-y
Figure Lengend Snippet: Up-regulated JAK1 and JAK2 are associated with liver fibrosis and liver disease in human and mice. A JAK1 and JAK2 immunohistochemistry (IHC) was performed in human liver tissues microarray of normal, cirrhosis, and cancer (× 100 magnification, scale bar = 100 μm). B JAK1 and JAK2 scores quantified by IHC in normal liver, liver cirrhosis, and liver cancer. C The IHC and Sirius red staining of JAK1 and JAK2 were performed in mouse normal and fibrosis for 6 weeks CCl 4 -induced or 8 weeks CCl 4 -induced liver tissues (× 100 and × 200 magnification, scale bar = 100 μm). D JAK1 and JAK2 scores quantified by IHC in normal liver, 6 weeks CCl 4 -induced liver fibrosis and 8 weeks CCl 4 -induced liver fibrosis. Data presented are means ± SD. ** P < 0.01; *** P < 0.001
Article Snippet: Human liver tissue microarray was purchased from Biomax, including 5 liver samples with normal liver tissue, 22 liver samples with liver cirrhosis, and 53 liver samples with liver cancer which were collected in US.
Techniques: Immunohistochemistry, Microarray, Staining